Recent News

• 09.16.2025 - Charles River Laboratories Announces Chief Financial Officer Transition
• 09.11.2025 - Charles River Collaborates to Enhance Oncology Manufacturing Portfolio, Advancing Research and Development of Cell and Gene Therapies to Treat Cancer
• 09.10.2025 - Charles River Laboratories at the Baird 2025 Global Healthcare Conference
• 09.09.2025 - Charles River Laboratories at the Morgan Stanley 23rd Annual Global Healthcare Conference
• 09.08.2025 - Charles River Laboratories to Present at Baird and Morgan Stanley Conferences
• 09.03.2025 - Charles River Enhances Cell Therapy Flex Platform through Collaboration with Akadeum Life Sciences
• 08.26.2025 - Charles River Joins EASYGEN Consortium, Supports Development of Bedside CAR-T Manufacturing
• 08.06.2025 - Q2 2025 Charles River Laboratories International, Inc. Earnings Conference Call
• 08.06.2025 - Charles River Laboratories Announces Second-Quarter 2025 Results

Recent Filings

• 09.16.2025 - EX-99.1 EX-99.1
• 09.16.2025 - 8-K Current report
• 08.22.2025 - 144 Report of proposed sale of securities
• 08.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.18.2025 - 144 Report of proposed sale of securities
• 08.18.2025 - 144 Report of proposed sale of securities
• 08.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 08.08.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.07.2025 - 144 Report of proposed sale of securities
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]